Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai HaiHe Raises $146.6 Million for Innovative Cancer Drugs

publication date: Feb 12, 2019

Shanghai HaiHe Biopharma announced a $146.6 million funding to support its portfolio of innovative cancer drugs. HaiHe has partnered with Shanghai Institute of Materia Medica, Chinese Academy of Science to develop novel cancer drugs for global markets. The company is testing ten candidates in clinical trials and five more in preclinical studies. Last year, HaiHe merged with RMX (Shanghai) Pharmaceutical Technology. The financing was led by Huagai Capital, a private equity investor. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital